6 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
positive outcome, an even broader range of metastatic PDAC patients may benefit from pelareorep-based therapy
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
outcome, an even broader range of metastatic PDAC patients may benefit from pelareorep-based therapy
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
LIBTAYO® with either FG-3165 or FG-3175 may result in added clinical benefit for patients. Under
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
the combination of pelareorep and mFOLFIRINOX produce a similarly positive outcome, an even broader range of metastatic PDAC patients may benefit from
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
the combination of pelareorep and mFOLFIRINOX produce a similarly positive outcome, an even broader range of metastatic PDAC patients may benefit from pelareorep
c5ygxvjh47i5lxtc 1a4tbb0vey5cgcmk3zu072iqrl79mfy2fom2p
ABBV
FGEN
3 Apr 24
an imaging agent called 89Zr-based CD46 PET to select patients most likely to benefit from FG-3246 in the Phase 2 study.
FibroGen
- Prev
- 1
- Next